|
Author (year) | Country | Sample size/sex | Mean age intervention/control | Duration (week)/study design | Population characteristics | Type of intervention (gr/day) | Intervention in placebo group (gr/day) | Outcomes |
|
Amoutzopoulo et al. (2013) [33] | Turkey | 89 (high hardaliye: 39 Low hardaliye: 33 C: 17)/both | High hardaliye: 37.44 Low hardaliye: 32.79 C: 34.18 | 6/P | Healthy adults | High hardaliye (500)/Low hardaliye (250) | Not receiving intervention | ↔TAC ↓MDA |
|
Bardagjy et al. (2018) [16] | USA | 20 (I: 20, C: 20)/both | 48.6 | 4/C | Healthy obese | Freeze-dried whole grape powder (60) | Placebo | ↔CRP ↔IL-6 ↔MCP-1 ↔ox-LDL ↔TNF-a |
|
Barona et al. (2012) [34] | USA | 24 (I: 40, C: 38)/M Dyslipidemia: 11 Nondyslipidemia: 13 | Dyslipidemia: 48.1 Nondyslipidemia: 53.9 | 4/C | Metabolic syndrome | Lyophilized whole grape powder (46) | Macronutrient-matched placebo | ↔TNF-a ↔IL-6 ↔IL-8 IL-10 (Dyslipidemia: ↓Non-dyslipidemia: ↑) |
|
Castilla et al. (2006) [12] | Spain | 38 (I: 26, C: 12)/both | 62/59.2 | 2/P | Hemodialysis | Concentrated red grape juice (100) | Not receiving intervention | ↓ ox-LDL ↑TEAC ↓MCP-1 ↔CRP |
|
Castilla et al. (2008) [35] | Spain | 16 (I: 8, C: 8)/both | Range: 33–79 y | 2/P | Hemodialysis | Concentrated red grape juice (1000) | Not receiving intervention | ↓ ox-LDL ↓MCP-1 ↔CRP |
|
Corredor et al. (2016) [36] | Spain | 39 (I :25, C: 14)/both | 66.16/59.71 | 24/P | Hemodialysis | Unfermented grape juice (100) | Not receiving intervention | ↔CRP |
|
Dani et al. (2020) [37] | Brazil | 20 (I: 10, C: 10)/F | 68/72 | 4/P | Healthy elderly women | Grape juice and exercise (400) | Placebo and exercise | ↔TBARS ↔Carbonil ↔SOD ↔CAT ↓IL-6 |
|
De Oliveira et al. (2021) [15] | Brazil | 19 (I: 10, C: 9)/both | 68.33/65.5 | 4/P | Parkinson | Grape juice (400) + aquatic exercise | No grape juice + aquatic exercise | ↔TBARS ↔Carbonyl ↔CAT ↔GPX ↔SOD |
|
Dohadwala et al. (2010) [38] | USA | 59 (I: 59, C: 59)/both | 40/44 | 8/C | Prehypertension and stage 1 hypertension | Grape juice (595) | Placebo juice | ↔CRP |
|
Duclos (2017) [39] | USA | 19 (I: 19, C: 19)/both | 30–70 | 4/C | Metabolic syndrome | Freeze-dried grape powder (60) | Matched placebo | ↔AOPPs ↔TBARS ↔TNF-a ↔MCP-1 ↔IL-6 |
|
Evans et al. (2014) [40] | Canada | 25 (I: 13, C: 12)/both | 46.1/38 | 6/P | Prehypertensive, overweight, and/or prediabetic | Whole grape extract (0.35) | Microcrystalline cellulose | ↔TAC ↔SOD ↔ox-LDL |
|
Goulart et al. (2020) [41] | Brazil | 20 (I: 20, C: 20)/both | 17.8 | 2/C | Judo athlete | Grape juice (400) | Placebo | ↔Carbonyl ↔TBARS ↑TAC ↓SOD ↔CAT |
|
Hollis et al. (2009) [42] | USA | 51 (I: 25, C: 26)/both | 22/28 | 12/P | Healthy adults | Concord grape juice (480) | Not receiving intervention | ↔ORAC |
|
Kaliora et al. (2016) [13] | Greece | 44 (I: 23, C: 21)/both | 50.7/51.6 | 24/P | NAFLD with nonsignificant fibrosis | Corinthian currants (36) + dietary counseling | Dietary counseling | ↔CRP ↓IL-6 ↔ox-LDL ↔TNF-a |
|
Kanellos et al. (2013) [43] | Greece | 48 (I: 26, C: 22)/both | 63.7/63 | 24/P | Diabetes (type 2) | Raisin (36) | Usual dietary habit | ↔hs-CRP ↔IL-6 ↔TNF-a ↑TAP ↔ox-LDL |
|
Kanellos et al. (2017) [44] | Greece | 33 (I: 20, C: 13)/both | 30.8/29.8 | 4/P | Healthy smokers | Raisin (90) | Not receiving intervention | ↔CRP ↔MDA ↔AOPPs ↔NO |
|
Lafay et al. (2009) [45] | France | 20 (I: 20, C: 20)/both | 21.6 | 4/C | Elite athletes | Grape extract (0.4) | Maltodextrin | ↑ORAC ↔Ox-LDL ↔SOD ↔GPx ↔CAT |
|
Martínez-Maqueda et al. (2018) [46] | Spain | 48 (I: 25, C: 23)/both | Range: 20–65 Mean: 42.6 | 6/C | Metabolic syndrome | Dried grape pomace (8) | Not receiving intervention | ↔hs-CRP |
|
Puglisi et al. (2008) [47] | USA | 22 (I: 10, C: 12)/both | 57.8/55 | 6/P | Men and postmenopausal women | Raisin (150) + walk | Walk | ↔TNF-a |
|
Rahbar et al. (2015) [48] | Iran | 69 (Red grape: 22, White grape: 24, C: 23)/both | Red grape: 50.5 White grape: 50.6 C: 52.5 | 8/P | Hypercholesterolemic adults | Condori red grapes/Shahroodi white grape (500) | 5 servings of other fruits except grapes | ↓TBARS ↑TAC |
|
Rankin et al. (2008) [49] | USA | 17 (I: 17, C: 17)/both | 26.5 | 2/C | Overweight | Raisin (90) | Isocaloric placebo | ↔CRP ↔IL-6 ↑ORAC |
|
Rowe et al. (2011) [50] | USA | 78 (I: 40, C: 38)/both | Range: 50–75 Mean: 57.9 | 9/P | Healthy individuals | Concord grape juice (260) | Concord grape-flavored placebo | ↔ORAC |
|
Shishehbor et al. (2021) [51] | Iran | 38 (I: 20, C: 18)/both | 39.11/42.8 | 5/P | Hyperlipidemic patients | Black seed raisin (90) | Not receiving intervention | ↔hs-CRP ↑TAC ↔MDA |
|
Tome’-Carneiro et al. (2013) [52] | Spain | 50 (I: 25, C: 25)/both | 58/59 | 52/P | Patients with stable coronary Artery disease | Grape extract (0.35) | Maltodextrin | ↔hs-CRP ↔TNF-a ↔IL-6 ↔IL-10 ↔IL-6/IL-10 |
|
Toscano et al. (2017) [53] | Brazil | 28 (I: 15, C: 13)/both | 42.7/36.3 | 4/P | Recreational runners | Grape juice (680) | Isocaloric juice | ↔MDA ↑TAC ↔hs-CRP |
|
Vaisman and Niv (2015) [54] | Israel | 45 (not mentioned separately)/both | 57.6/56.4 | 12/P | Pre- and mild hypertension | Red grape cell powder (0.4) | Colored maltodextrin powder (0.2) | ↔CRP |
|
Yubero et al. (2013) [55] | Spain | 60 (I: 30, C: 30)/both | Range: 34–65 Mean: 51 | 8/P | Healthy | Polyphenol-rich pomace grape extract supplement (Eminol) (0.7) | Maltodextrin | ↔TNF-a ↑ORAC ↔ox-LDL |
|
Zern et al. (2005) [14] | USA | 24 (I: 24, C: 24)/F | 39.7 | 4/C | Premenopausal women | A lyophilized grape powder (36) | Equal ratio of fructose and dextrose | ↔hs-CRP ↔IL-6 ↓TNF-a |
USA | 20 (I: 20, C: 20)/F | 58.5 | 4/C | Postmenopausal women | A lyophilized grape powder (36) | Equal ratio of fructose and dextrose | ↔hs-CRP ↔IL-6 ↓TNF-a |
|
Zunino et al. (2014) [17] | USA | 59 (I: 24, C: 24)/both | F: 34.7/M: 37.1 | 3/C | Healthy obese | Freeze-dried whole grape powder (92) | Placebo | ↔IL-1b ↔IL-6 ↔IL-8 ↔TNF-a ↔CRP ↔ORAC ↔ox-LDL |
|